HC Wainwright & Co. Maintains Buy on Pasithea Therapeutics, Raises Price Target to $4
Pasithea's PAS-004 Shrinks Skin Tumors in All 15 Evaluable Patients
Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 European Neurofibromatosis Conference
Pasithea’s PAS-004 Reduces Cutaneous Neurofibromas In All 15 Evaluable Participants, 41% Median Best Reduction, 46% At Planned Phase 2 Doses, With No Treatment-Related Serious Adverse Events
Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF)
Pasithea Therapeutics Says FDA Clears IND Application For Randomized, Placebo-Controlled Phase 2 Clinical Trial For PAS-004 In Patients With NF1 Associated Cutaneous Neurofibromas
Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026
Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026
Pasithea Therapeutics Presents Phase I Dose-Escalation Trial Of PAS-004 Inhibitor; Announces No Dose Limiting Toxicities Seen; No Participant Discontinued PAS-004; No Grade 3, Higher Observed
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
Pasithea Sets November Debut For Early PAS-004 Clinical Trial Results
Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
Pasithea Therapeutics To Present Phase I Dose-Escalation Study Of Safety, Pharmacokinetics Of PAS-004, Macrocyclic MEK Inhibitor, For Treatment Of MAPK Pathway Driven Advanced Solid Tumors At ESMO Congress 2026
Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion
Pasithea Therapeutics Announces Updated Interim Safety And Clinical Activity Data From Its Trial Evaluating PAS-004 In Patients With MAPK Pathway-Driven Advanced Solid Tumors; PAS-004 Has Been Well-Tolerated, With All Treatment-Related Adverse Events Being Grade 1 Or 2
HC Wainwright & Co. Reiterates Buy on Pasithea Therapeutics, Maintains $3 Price Target
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
Pasithea Therapeutics Amends Clinical Study Protocol For Phase 1/1b Trial Of PAS-004 In Neurofibromatosis Type 1 Patients With Symptomatic Inoperable, Incompletely Resected, Or Recurrent Plexiform Neurofibroma
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.